Cercador de Publicacions

La producció científica dels nostres investigadors i investigadores és molt elevada. L'any 2022 es van publicar 1.629 articles a revistes científiques amb un factor d'impacte global que va superar els 15.000 punts.

Correction: Randomized prospective study evaluating tenofovir disoproxil fumarate prophylaxis against hepatitis B virus reactivation in anti-HBc-positive patients with rituximab-based regimens to treat hematologic malignancies: The Preblin study.

PMID: 29940039
Revista: PLoS One
Any: 2018
Referència: PLoS One. 2018 Jun 25;13(6):e0199926. doi: 10.1371/journal.pone.0199926. eCollection 2018.
Factor d'impacte: 2.766
Tipus de publicació: Carta o abstract
Autors: Morillas, Rosa M, Garcia-Retortillo, Montserrat, Martin, Leticia, Prieto, Martin, Gutierrez, Maria L, Suarez, Emilio, Rubio, Mariano Gomez, Lopez, Javier, Castillo, Pilar, Rodriguez, Manuel et al.
DOI: 10.1371/journal.pone.0199926

Correction: Randomized prospective study evaluating tenofovir disoproxil fumarate prophylaxis against hepatitis B virus reactivation in anti-HBc-positive patients with rituximab-based regimens to treat hematologic malignancies: The Preblin study.

PMID: 29940039
Revista: PLoS One
Any: 2018
Referència: PLoS One. 2018 Jun 25;13(6):e0199926. doi: 10.1371/journal.pone.0199926. eCollection 2018.
Factor d'impacte:
Tipus de publicació: Carta o abstract
Autors: Buti, Maria; Calleja, Jose L; Castillo, Pilar; Esteban, Rafael; Garcia-Retortillo, Montserrat; Gutierrez, Maria L; Lopez, Javier; Manzano, Maria L; Martin, Leticia; Morano, Luis E et al.
DOI: 10.1371/journal.pone.0199926

Correction: The Adaptor 3BP2 Is Required for KIT Receptor Expression and Human Mast Cell Survival.

PMID: 29282310
Revista: JOURNAL OF IMMUNOLOGY
Any: 2018
Referència: J Immunol. 2018 Feb 1;200(3):1227. doi: 10.4049/jimmunol.1701691. Epub 2017 Dec 27.
Factor d'impacte: 4.539
Tipus de publicació: Carta o abstract
Autors: Ainsua-Enrich, Erola, Serrano-Candelas, Eva, Alvarez-Errico, Damiana, Picado, Cesar, Sayos, Joan, Rivera, Juan, Martin, Margarita et al.
DOI: 10.4049/jimmunol.1701691

Correction: The Adaptor 3BP2 Is Required for KIT Receptor Expression and Human Mast Cell Survival.

PMID: 29282310
Revista: JOURNAL OF IMMUNOLOGY
Any: 2018
Referència: J Immunol. 2018 Feb 1;200(3):1227. doi: 10.4049/jimmunol.1701691. Epub 2017 Dec 27.
Factor d'impacte:
Tipus de publicació: Carta o abstract
Autors: Ainsua-Enrich, Erola; Alvarez-Errico, Damiana; Martin, Margarita; Picado, Cesar; Rivera, Juan; Sayos, Joan; Serrano-Candelas, Eva et al.
DOI: 10.4049/jimmunol.1701691

Correction to: A Phase II Study Evaluating Combined Neoadjuvant Cetuximab and Chemotherapy Followed by Chemoradiotherapy and Concomitant Cetuximab in Locoregional Oesophageal Cancer Patients.

PMID: 29243205
Revista: Targeted Oncology
Any: 2018
Referència: Target Oncol. 2018 Feb;13(1):79. doi: 10.1007/s11523-017-0544-z.
Factor d'impacte: 3.877
Tipus de publicació: Carta o abstract
Autors: Ramos, Francisco Javier, Galan, Maica, Lopez, Rafael, Garcia-Alfonso, Pilar, Ales-Martinez, Jose Enrique, Queralt, Bernardo, Anton, Antonio, Carrato, Alfredo, Gravalos, Cristina, Mendez-Vidal, Maria Jose et al.
DOI: 10.1007/s11523-017-0544-z

Correction to: A Phase II Study Evaluating Combined Neoadjuvant Cetuximab and Chemotherapy Followed by Chemoradiotherapy and Concomitant Cetuximab in Locoregional Oesophageal Cancer Patients.

PMID: 29243205
Revista: Targeted Oncology
Any: 2018
Referència: Target Oncol. 2018 Feb;13(1):79. doi: 10.1007/s11523-017-0544-z.
Factor d'impacte:
Tipus de publicació: Carta o abstract
Autors: Ales-Martinez, Jose Enrique; Alsina, Maria; Anton, Antonio; Aranda, Enrique; Carrato, Alfredo; de Mena, Inmaculada Ruiz; Galan, Maica; Garcia-Alfonso, Pilar; Giralt, Jordi; Gravalos, Cristina et al.
DOI: 10.1007/s11523-017-0544-z

Correction to: A phase I-II study of plerixafor in combination with fludarabine, idarubicin, cytarabine, and G-CSF (PLERIFLAG regimen) for the treatment of patients with the first early-relapsed or refractory acute myeloid leukemia.

PMID: 29473097
Revista: ANNALS OF HEMATOLOGY
Any: 2018
Referència: Ann Hematol. 2018 May;97(5):923. doi: 10.1007/s00277-018-3277-x.
Factor d'impacte: 2.845
Tipus de publicació: Carta o abstract
Autors: Bergua, Juan, Rodriguez-Veiga, Rebeca, Esteve, Jordi, Vives, Susana, Serrano, Josefina, Vidriales, Belen, Salamero, Olga, Cordon, Lourdes, Sempere, Amparo, Jimenez-Ubieto, Ana et al.
DOI: 10.1007/s00277-018-3277-x

Correction to: A phase I-II study of plerixafor in combination with fludarabine, idarubicin, cytarabine, and G-CSF (PLERIFLAG regimen) for the treatment of patients with the first early-relapsed or refractory acute myeloid leukemia.

PMID: 29473097
Revista: ANNALS OF HEMATOLOGY
Any: 2018
Referència: Ann Hematol. 2018 May;97(5):923. doi: 10.1007/s00277-018-3277-x.
Factor d'impacte:
Tipus de publicació: Carta o abstract
Autors: Benavente, Celina; Bergua, Juan; Boluda, Blanca; Cordon, Lourdes; Diaz-Beya, Marina; Esteve, Jordi; Garrido, Ana; Jimenez-Ubieto, Ana; Martinez, Pilar; Martinez-Cuadron, David et al.
DOI: 10.1007/s00277-018-3277-x

Correction to: Blood lymphocyte subsets identify optimal responders to IFN-beta in MS.

PMID: 29177546
Revista: JOURNAL OF NEUROLOGY
Any: 2018
Referència: J Neurol. 2018 Jan;265(1):32. doi: 10.1007/s00415-017-8679-5.
Factor d'impacte: 3.783
Tipus de publicació: Carta o abstract
Autors: Alenda, Raquel, Costa-Frossard, Lucienne, Alvarez-Lafuente, Roberto, Espejo, Carmen, Rodriguez-Martin, Eulalia, Sainz de la Maza, Susana, Villarrubia, Noelia, Rio, Jordi, Dominguez-Mozo, Maria I, Alvarez-Cermeno, Jose C et al.
DOI: 10.1007/s00415-017-8679-5

Correction to: Blood lymphocyte subsets identify optimal responders to IFN-beta in MS.

PMID: 29177546
Revista: JOURNAL OF NEUROLOGY
Any: 2018
Referència: J Neurol. 2018 Jan;265(1):32. doi: 10.1007/s00415-017-8679-5.
Factor d'impacte:
Tipus de publicació: Carta o abstract
Autors: Alenda, Raquel; Alvarez-Cermeno, Jose C; Alvarez-Lafuente, Roberto; Costa-Frossard, Lucienne; Dominguez-Mozo, Maria I; Espejo, Carmen; Montalban, Xavier; Rio, Jordi; Rodriguez-Martin, Eulalia; Sainz de la Maza, Susana et al.
DOI: 10.1007/s00415-017-8679-5

Correction to: Breast-conserving surgery following neoadjuvant therapy-a systematic review on surgical outcomes.

PMID: 29327297
Revista: BREAST CANCER RESEARCH AND TREATMENT
Any: 2018
Referència: Breast Cancer Res Treat. 2018 Feb;168(1):13-15. doi: 10.1007/s10549-017-4632-7.
Factor d'impacte: 3.605
Tipus de publicació: Carta o abstract
Autors: Krekel, Nicole M A, Schoonmade, Linda J, Meijer, Sybren, Rubio, Isabel T, van den Tol, M Petrousjka, Spronk, Pauline E, Negenborn, Vera L, Volders, Jose H et al.
DOI: 10.1007/s10549-017-4632-7

Correction to: Breast-conserving surgery following neoadjuvant therapy-a systematic review on surgical outcomes.

PMID: 29327297
Revista: BREAST CANCER RESEARCH AND TREATMENT
Any: 2018
Referència: Breast Cancer Res Treat. 2018 Feb;168(1):13-15. doi: 10.1007/s10549-017-4632-7.
Factor d'impacte:
Tipus de publicació: Carta o abstract
Autors: Krekel, Nicole M A; Meijer, Sybren; Negenborn, Vera L; Rubio, Isabel T; Schoonmade, Linda J; Spronk, Pauline E; van den Tol, M Petrousjka; Volders, Jose H et al.
DOI: 10.1007/s10549-017-4632-7

Correction to: CSF inflammatory markers and neurocognitive function after addition of maraviroc to monotherapy darunavir/ritonavir in stable HIV patients: the CINAMMON study.

PMID: 29318452
Revista: JOURNAL OF NEUROVIROLOGY
Any: 2018
Referència: J Neurovirol. 2018 Jun;24(3):388-389. doi: 10.1007/s13365-017-0613-1.
Factor d'impacte: 3.228
Tipus de publicació: Carta o abstract
Autors: Barber, T J, Imaz, A, Boffito, M, Niubo, J, Pozniak, A, Fortuny, R, Davies, N, Mandalia, S, Podzamczer, D, Gazzard, B et al.
DOI: 10.1007/s13365-017-0613-1

Correction to: CSF inflammatory markers and neurocognitive function after addition of maraviroc to monotherapy darunavir/ritonavir in stable HIV patients: the CINAMMON study.

PMID: 29318452
Revista: JOURNAL OF NEUROVIROLOGY
Any: 2018
Referència: J Neurovirol. 2018 Jun;24(3):388-389. doi: 10.1007/s13365-017-0613-1.
Factor d'impacte:
Tipus de publicació: Carta o abstract
Autors: Alonso, J; Barber, T J; Boffito, M; Davies, N; Fortuny, R; Gazzard, B; Imaz, A; Mandalia, S; Niubo, J; Podzamczer, D et al.
DOI: 10.1007/s13365-017-0613-1

Correction to: First clinical symptom as a prognostic factor in systemic sclerosis: results of a retrospective nationwide cohort study.

PMID: 29931516
Revista: CLINICAL RHEUMATOLOGY
Any: 2018
Referència: Clin Rheumatol. 2018 Aug;37(8):2303-2304. doi: 10.1007/s10067-018-4179-y.
Factor d'impacte: 2.141
Tipus de publicació: Carta o abstract
Autors: Callejas Moraga, E, Calvo, E, Carbonell, C, Castillo, M J, Chamorro, A J, Colunga, D, Corbella, X, Egurbide, M V, Espinosa, G, Fonollosa, V et al.
DOI: 10.1007/s10067-018-4179-y

Correction to: First clinical symptom as a prognostic factor in systemic sclerosis: results of a retrospective nationwide cohort study.

PMID: 29931516
Revista: CLINICAL RHEUMATOLOGY
Any: 2018
Referència: Clin Rheumatol. 2018 Aug;37(8):2303-2304. doi: 10.1007/s10067-018-4179-y.
Factor d'impacte:
Tipus de publicació: Carta o abstract
Autors: Callejas Moraga, E; Calvo, E; Carbonell, C; Castillo, Alfredo Guillen-Del; Castillo, M J; Castillo-Palma, Maria Jesus; Chamorro, A J; Colunga, D; Colunga-Arguelles, Dolores; Corbella, X et al.
DOI: 10.1007/s10067-018-4179-y

Correction to: Manifesting heterozygotes in McArdle disease: a myth or a reality-role of statins.

PMID: 30030676
Revista: JOURNAL OF INHERITED METABOLIC DISEASE
Any: 2018
Referència: J Inherit Metab Dis. 2018 Nov;41(6):1295. doi: 10.1007/s10545-018-0236-6.
Factor d'impacte: 4.092
Tipus de publicació: Carta o abstract
Autors: Nunez-Manchon, Judit, Ballester-Lopez, Alfonsina, Koehorst, Emma, Linares-Pardo, Ian, Coenen, Danielle, Ara, Ignacio, Rodriguez-Lopez, Carlos, Ramos-Fransi, Alba, Martinez-Pineiro, Alicia, Lucente, Giuseppe et al.
DOI: 10.1007/s10545-018-0236-6

Correction to: Manifesting heterozygotes in McArdle disease: a myth or a reality-role of statins.

PMID: 30030676
Revista: JOURNAL OF INHERITED METABOLIC DISEASE
Any: 2018
Referència: J Inherit Metab Dis. 2018 Nov;41(6):1295. doi: 10.1007/s10545-018-0236-6.
Factor d'impacte:
Tipus de publicació: Carta o abstract
Autors: Almendrote, Miriam; Ara, Ignacio; Arenas, Joaquin; Ballester-Lopez, Alfonsina; Coenen, Danielle; Coll-Canti, Jaume; de Castro, Mauricio; Koehorst, Emma; Linares-Pardo, Ian; Lucente, Giuseppe et al.
DOI: 10.1007/s10545-018-0236-6

Correction to: Recommendations for the follow-up care of female breast cancer survivors: a guideline of the Spanish Society of Medical Oncology (SEOM), Spanish Society of Primary Care Physicians (SEMERGEN), Spanish Society for Family and Community Medicine (SEMFYC), Spanish Society for General and Family Physicians (SEMG), Spanish Society of Obstetrics and Gynecology (SEGO), Spanish Society of Radiation Oncology (SEOR), Spanish Society of Senology and Breast Pathology (SESPM), and Spanish Society of Cardiology (SEC).

PMID: 29294225
Revista: Clinical & Translational Oncology
Any: 2018
Referència: Clin Transl Oncol. 2018 Jun;20(6):803-804. doi: 10.1007/s12094-017-1822-z.
Factor d'impacte: 2.392
Tipus de publicació: Carta o abstract
Autors: Fernandez, T, Santolaya, F, Ruiz, A, Munoz, M, Montero, A, Barnadas, A, Algara, M, Cordoba, O, Casas, A, Gonzalez, M et al.
DOI: 10.1007/s12094-017-1822-z

Correction to: Recommendations for the follow-up care of female breast cancer survivors: a guideline of the Spanish Society of Medical Oncology (SEOM), Spanish Society of Primary Care Physicians (SEMERGEN), Spanish Society for Family and Community Medicine (SEMFYC), Spanish Society for General and Family Physicians (SEMG), Spanish Society of Obstetrics and Gynecology (SEGO), Spanish Society of Radiation Oncology (SEOR), Spanish Society of Senology and Breast Pathology (SESPM), and Spanish Society of Cardiology (SEC).

PMID: 29294225
Revista: Clinical & Translational Oncology
Any: 2018
Referència: Clin Transl Oncol. 2018 Jun;20(6):803-804. doi: 10.1007/s12094-017-1822-z.
Factor d'impacte:
Tipus de publicació: Carta o abstract
Autors: Algara, M; Barnadas, A; Casas, A; Cordoba, O; Fernandez, T; Gonzalez, M; Marzo, M; Montero, A; Munoz, M; Ruiz, A et al.
DOI: 10.1007/s12094-017-1822-z

Correction to: SEOM clinical guidelines for the treatment of metastatic prostate cancer (2017).

PMID: 29305743
Revista: Clinical & Translational Oncology
Any: 2018
Referència: Clin Transl Oncol. 2018 Jan;20(1):110-111. doi: 10.1007/s12094-017-1823-y.
Factor d'impacte: 2.392
Tipus de publicació: Carta o abstract
Autors: Cassinello, J, Arranz, J A, Piulats, J M, Sanchez, A, Perez-Valderrama, B, Mellado, B, Climent, M A, Olmos, D, Carles, J, Lazaro, M et al.
DOI: 10.1007/s12094-017-1823-y

Correction to: SEOM clinical guidelines for the treatment of metastatic prostate cancer (2017).

PMID: 29305743
Revista: Clinical & Translational Oncology
Any: 2018
Referència: Clin Transl Oncol. 2018 Jan;20(1):110-111. doi: 10.1007/s12094-017-1823-y.
Factor d'impacte:
Tipus de publicació: Carta o abstract
Autors: Arranz, J A; Carles, J; Cassinello, J; Climent, M A; Lazaro, M; Mellado, B; Olmos, D; Perez-Valderrama, B; Piulats, J M; Sanchez, A et al.
DOI: 10.1007/s12094-017-1823-y

Correction to: The Intensive Care Global Study on Severe Acute Respiratory Infection (IC-GLOSSARI): a multicenter, multinational, 14-day inception cohort study.

PMID: 29138898
Revista: INTENSIVE CARE MEDICINE
Any: 2018
Referència: Intensive Care Med. 2018 Jan;44(1):144-152. doi: 10.1007/s00134-017-4979-6.
Factor d'impacte: 15.008
Tipus de publicació: Carta o abstract
Autors: Lehmke, J, Sakr, Yasser, Ferrer, Ricard, Reinhart, Konrad, Beale, Richard, Rhodes, Andrew, Moreno, Rui, Timsit, Jean Francois, Brochard, Laurent, Thompson, B Taylor et al.
DOI: 10.1007/s00134-017-4979-6

Correction to: The Intensive Care Global Study on Severe Acute Respiratory Infection (IC-GLOSSARI): a multicenter, multinational, 14-day inception cohort study.

PMID: 29138898
Revista: INTENSIVE CARE MEDICINE
Any: 2018
Referència: Intensive Care Med. 2018 Jan;44(1):144-152. doi: 10.1007/s00134-017-4979-6.
Factor d'impacte:
Tipus de publicació: Carta o abstract
Autors: Adamik, B; Afonso, S; Aguilar, G; Aisa, T; Albarrak, M; Albis, A; Alexander, P; Allgaeuer, S; Almekhlafi, G; Alsheikhly, A S et al.
DOI: 10.1007/s00134-017-4979-6

Publicacions

Cercador de Publicacions

Correction: Randomized prospective study evaluating tenofovir disoproxil fumarate prophylaxis against hepatitis B virus reactivation in anti-HBc-positive patients with rituximab-based regimens to treat hematologic malignancies: The Preblin study.

Correction: Randomized prospective study evaluating tenofovir disoproxil fumarate prophylaxis against hepatitis B virus reactivation in anti-HBc-positive patients with rituximab-based regimens to treat hematologic malignancies: The Preblin study.

Correction: The Adaptor 3BP2 Is Required for KIT Receptor Expression and Human Mast Cell Survival.

Correction: The Adaptor 3BP2 Is Required for KIT Receptor Expression and Human Mast Cell Survival.

Correction to: A Phase II Study Evaluating Combined Neoadjuvant Cetuximab and Chemotherapy Followed by Chemoradiotherapy and Concomitant Cetuximab in Locoregional Oesophageal Cancer Patients.

Correction to: A Phase II Study Evaluating Combined Neoadjuvant Cetuximab and Chemotherapy Followed by Chemoradiotherapy and Concomitant Cetuximab in Locoregional Oesophageal Cancer Patients.

Correction to: A phase I-II study of plerixafor in combination with fludarabine, idarubicin, cytarabine, and G-CSF (PLERIFLAG regimen) for the treatment of patients with the first early-relapsed or refractory acute myeloid leukemia.

Correction to: A phase I-II study of plerixafor in combination with fludarabine, idarubicin, cytarabine, and G-CSF (PLERIFLAG regimen) for the treatment of patients with the first early-relapsed or refractory acute myeloid leukemia.

Correction to: Blood lymphocyte subsets identify optimal responders to IFN-beta in MS.

Correction to: Blood lymphocyte subsets identify optimal responders to IFN-beta in MS.

Correction to: Breast-conserving surgery following neoadjuvant therapy-a systematic review on surgical outcomes.

Correction to: Breast-conserving surgery following neoadjuvant therapy-a systematic review on surgical outcomes.

Correction to: CSF inflammatory markers and neurocognitive function after addition of maraviroc to monotherapy darunavir/ritonavir in stable HIV patients: the CINAMMON study.

Correction to: CSF inflammatory markers and neurocognitive function after addition of maraviroc to monotherapy darunavir/ritonavir in stable HIV patients: the CINAMMON study.

Correction to: First clinical symptom as a prognostic factor in systemic sclerosis: results of a retrospective nationwide cohort study.

Correction to: First clinical symptom as a prognostic factor in systemic sclerosis: results of a retrospective nationwide cohort study.

Correction to: Manifesting heterozygotes in McArdle disease: a myth or a reality-role of statins.

Correction to: Manifesting heterozygotes in McArdle disease: a myth or a reality-role of statins.

Correction to: SEOM clinical guidelines for the treatment of metastatic prostate cancer (2017).

Correction to: SEOM clinical guidelines for the treatment of metastatic prostate cancer (2017).

Correction to: The Intensive Care Global Study on Severe Acute Respiratory Infection (IC-GLOSSARI): a multicenter, multinational, 14-day inception cohort study.

Correction to: The Intensive Care Global Study on Severe Acute Respiratory Infection (IC-GLOSSARI): a multicenter, multinational, 14-day inception cohort study.

Patronat:

Col·labora:

Acreditacions: